Madrigal Pharmaceuticals, Inc. (MDGL) Debt by Year
Madrigal Pharmaceuticals, Inc. carried $339.9M in long-term debt against $198.7M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 189.1% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Madrigal Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
MDGL Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $339.9M+189.1% | $117.6M+1.8% | $115.5M+134.3% | $49.3M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $198.7M+98.7% | $100.0M+0.1% | $99.9M-69.9% | $331.5M+814.1% | $36.3M-32.8% | $54.0M+15.6% | $46.7M-18.6% | $57.4M-61.4% | $148.6M+676.3% | $19.1M+6156.5% | $306K+106.7% | $148K-99.7% | $48.5M-40.5% | $81.5M+171.0% | $30.1M |
MDGL Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $340.8M+187.9% | $340.3M+188.4% | $339.9M+189.1% | $339.8M+190.2% | $118.4M+1.5% | $118.0M+1.6% | $117.6M+1.8% | $117.1M+2.1% | $116.6M+17.5% | $116.1M+38.3% | $115.5M+134.3% | $114.7M+134.2% |
| Cash & Equivalents | $292.7M+57.2% | $227.0M+23.6% | $198.7M+98.7% | $295.7M+27.1% | $186.2M-62.4% | $183.6M-70.5% | $100.0M+0.1% | $232.7M+275.0% | $494.6M+540.7% | $622.5M+449.4% | $99.9M-69.9% | $62.1M+4.6% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Madrigal Pharmaceuticals, Inc. financials
Frequently Asked Questions
What was Madrigal Pharmaceuticals, Inc.'s long-term debt in fiscal year 2025?
Madrigal Pharmaceuticals, Inc. carried $339.9M in long-term debt against $198.7M in cash and equivalents at the end of fiscal year 2025.
How fast is Madrigal Pharmaceuticals, Inc.'s long-term debt growing?
Madrigal Pharmaceuticals, Inc. (MDGL) long-term debt rose by 189.1% year over year, from $117.6M to $339.9M in fiscal year 2025.
What was Madrigal Pharmaceuticals, Inc.'s long-term debt in the most recent quarter?
Madrigal Pharmaceuticals, Inc. (MDGL) reported $340.8M in long-term debt in Q2 2026. This represents an increase of 187.9% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Madrigal Pharmaceuticals, Inc. (MDGL) reported on that line in every period on record.